Noguchi H, Matsumoto T, Kimura U, et al. - Fosravuconazole, a novel oral antifungal drug developed in Japan, is used to treat tinea unguium since 2018. It has been identified to have excellent oral absorbability and systemic bioavailability that allow short‐duration therapy of 3 months. Further, there is no contraindication for any concomitant drugs due to the presence of the mild inhibitor of cytochrome P450 enzyme which is responsible for polypharmacy adverse effects. Hence, elderly patients can be administered this drug safely. Oral fosravuconazole 100 mg was administered once daily for 12 weeks to elderly patients (≥ 65 years old) with severe onychomycosis (≥ 50% nail involvement). Improvement in the rate of involvement was noted from 86.6% to 28.1%. The efficacy (ie, percentage of those rated as “improved” and better) and cure rate of 83.8% (31/37) and 29.7% (11/37), respectively, was observed. In addition, when considering the thin nail group (< 3 mm), they noted the efficacy and cure rate of 88.2% (15/17) and 58.8% (10/17), respectively. Although 21.6% (8/37) showed increased serum γ‐glutamyltransferase levels, recovery without any specific treatments occurred in all patients.